MX393201B - Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades - Google Patents

Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades

Info

Publication number
MX393201B
MX393201B MX2019006880A MX2019006880A MX393201B MX 393201 B MX393201 B MX 393201B MX 2019006880 A MX2019006880 A MX 2019006880A MX 2019006880 A MX2019006880 A MX 2019006880A MX 393201 B MX393201 B MX 393201B
Authority
MX
Mexico
Prior art keywords
sub
compounds
group
diseases
glutaminil
Prior art date
Application number
MX2019006880A
Other languages
English (en)
Other versions
MX2019006880A (es
Inventor
Anastasia Vladimirovna Rydlovskaya
Tatyana Alexandrovna Kromova
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2017118350A external-priority patent/RU2665633C1/ru
Priority claimed from RU2017137615A external-priority patent/RU2662559C1/ru
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of MX2019006880A publication Critical patent/MX2019006880A/es
Publication of MX393201B publication Critical patent/MX393201B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02005—Glutaminyl-peptide cyclotransferase (2.3.2.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La invencion se refiere a la quimica de sustancias organicas, farmacologia y medicina, y se relaciona al tratamiento de enfermedades asociadas y con la actividad aberrante de celulas del sistema inmune, mas particularmente para el tratamiento de enfermedades del pulmon, del tracto respiratorio y abdominales, malestar por radiacion y sindrome de dolor, y tambien otras enfermedades al utilizar compuestos de formula (A) [ver fórmula (A)] en donde R1 es un grupo -C(O)-R2-C(O)- o -R2-C(O)-, donde R2 es un grupo -(CH2)n- opcionalmente sustituido con uno o dos alquilos de C1-C6, o fenilo, n es un entero de 0 a 4; en donde los compuestos se seleccionan del grupo que consiste del grupo de compuestos como se establece en la descripcion; estos compuestos, asi como las sales farmaceuticamente aceptables de los mismos, son altamente eficaces para inhibir la glutaminil ciclasa, que esta involucrada, en particular, en procesos de modificacion post-traduccional de quimiocinas y quimiotaxis de monocitos, macrofagos y otras celulas del sistema inmune; esta invencion tambien se refiere a composiciones farmaceuticas que comprenden una cantidad terapeuticamente eficaz de los compuestos de formula (A) como se definieron anteriormente.
MX2019006880A 2017-05-26 2018-05-24 Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades MX393201B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2017118350A RU2665633C1 (ru) 2017-05-26 2017-05-26 Новый ингибитор глутаминилциклаз и его применение
RU2017137615A RU2662559C1 (ru) 2017-10-27 2017-10-27 Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей
PCT/RU2018/050058 WO2018217139A1 (ru) 2017-05-26 2018-05-24 Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний

Publications (2)

Publication Number Publication Date
MX2019006880A MX2019006880A (es) 2019-08-01
MX393201B true MX393201B (es) 2025-03-24

Family

ID=64396616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006880A MX393201B (es) 2017-05-26 2018-05-24 Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades

Country Status (12)

Country Link
US (2) US11845740B2 (es)
EP (2) EP3632433B1 (es)
JP (2) JP7293114B2 (es)
KR (3) KR102694423B1 (es)
CN (3) CN118141807A (es)
AU (3) AU2018273483B2 (es)
CA (1) CA3046196A1 (es)
IL (1) IL267077B (es)
MX (1) MX393201B (es)
UA (1) UA124636C2 (es)
WO (1) WO2018217139A1 (es)
ZA (1) ZA201903828B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2647438C2 (ru) * 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
EP3632433B1 (en) * 2017-05-26 2025-12-24 Vladimir Evgenievich Nebolsin Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
RU2685277C1 (ru) * 2018-05-24 2019-04-17 Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных
CN114874186B (zh) * 2022-05-16 2023-07-11 深圳大学 一种谷氨酰胺酰基环化酶同工酶抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
BRPI0808170A2 (pt) * 2007-03-01 2014-07-08 Probiodrug Ag Uso de inibidores de glutaminil ciclase
GB2447017A (en) * 2007-03-01 2008-09-03 Probiodrug Ag New use for inhibitors of glutaminyl peptide cyclotransferinase
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
HK1223093A1 (zh) 2013-05-28 2017-07-21 Viamet Pharmaceuticals (NC), Inc. 杀真菌组合物
CN106231901A (zh) 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
KR20160145640A (ko) 2014-04-15 2016-12-20 다우 아그로사이언시즈 엘엘씨 살진균제로서의 금속효소 억제제 화합물
RU2647438C2 (ru) * 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
DE102015011780A1 (de) 2015-09-16 2017-03-16 Hochschule Anhalt Neue Glutaminylcyclase-lnhibitoren
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
EP3632433B1 (en) * 2017-05-26 2025-12-24 Vladimir Evgenievich Nebolsin Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases

Also Published As

Publication number Publication date
KR102694423B1 (ko) 2024-08-13
WO2018217139A4 (ru) 2018-12-20
AU2024219478A1 (en) 2024-10-03
JP2023071720A (ja) 2023-05-23
EP3632433B1 (en) 2025-12-24
CN118141807A (zh) 2024-06-07
UA124636C2 (uk) 2021-10-20
KR102714537B1 (ko) 2024-10-11
US11845740B2 (en) 2023-12-19
US20200087285A1 (en) 2020-03-19
EP4335509B1 (en) 2026-03-11
ZA201903828B (en) 2023-02-22
EP4335509A2 (en) 2024-03-13
JP7293114B2 (ja) 2023-06-19
KR20240035920A (ko) 2024-03-18
IL267077B (en) 2022-07-01
EP3632433A1 (en) 2020-04-08
CN110087650A (zh) 2019-08-02
MX2019006880A (es) 2019-08-01
WO2018217139A1 (ru) 2018-11-29
CA3046196A1 (en) 2018-11-29
EP3632433A4 (en) 2021-03-03
BR112019012597A2 (pt) 2019-11-19
AU2018273483B2 (en) 2024-06-13
JP2021533078A (ja) 2021-12-02
AU2024219477A1 (en) 2024-10-03
KR20240035919A (ko) 2024-03-18
AU2018273483A1 (en) 2019-06-20
EP4335509A3 (en) 2024-06-05
KR20200010164A (ko) 2020-01-30
IL267077A (en) 2019-10-31
US20240116898A1 (en) 2024-04-11
CN110087650B (zh) 2024-03-22
CN118141806A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2023007192A (es) Inhibidores de prmt5.
PH12021550310A1 (en) Novel sulfonamideurea compounds
JOP20200154B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
NZ777871A (en) Small molecule modulators of il-17
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
EP4335509A3 (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
CY1116274T1 (el) Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения